Solowin Holdings Ordinary Share
NASDAQ:AXGFinancial - Capital Markets
-$0.02 today
- Market cap
- $56.55M
- Beta
- -0.23
- P/E (TTM)
- -265.7
- EPS (TTM)
- -$0.01
Volume 0.90M
Average 0.24M
AXG Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Solowin Holdings Ordinary ShareNASDAQ: AXG
Gross Profit · Q2 FY2026 · quarter ended Sep 2025
Gross profit declines year over year
Q2 FY2026 gross profit of $20.48K fell 79.9% year over year. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Gross profit amounted to 76.2% of revenue in FY2025, down 22.1 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 275.5K USD
- Year-over-year change
- -48.9%
- 4-year CAGR
- +27.6%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 275.5K | -48.9% |
| FY2024 | 2024-03-31 | 538.82K | -4.2% |
| FY2023 | 2023-03-31 | 562.59K | +137.0% |
| FY2022 | 2022-03-31 | 237.4K | +128.6% |
| FY2021 | 2021-03-31 | 103.83K | — |
Gross Profit vs competitors
How AXG compares with its peers on the latest reported figures
- AXG's FY2025 gross profit of $275.5K is the lowest of the 3 companies compared; the peer median is $3.75B.
- Its year-over-year change of -48.9% is the lowest of 3, against a peer median of +541.6%.
- Gross profit amounts to 76.2% of revenue for AXG, versus a peer median of 76.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $7.45B | +7.2% | +1.3% | 77.8% | |
BCICBCP Investment Corporation | LTM Mar 2026 | $44.82M | +1076.0% | — | 74.4% |
AXGSolowin Holdings Ordinary Share | FY2025 | $275.5K | -48.9% | +5.1% | 76.2% |
| Peer median (excluding AXG) | $3.75B | +541.6% | +1.3% | 76.1% | |
Competitors are the stored peer set for AXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 152.33K | 418.27K | 568.08K | 548.41K | 361.73K |
| Cost of Revenue | 48.5K | 180.87K | 5.49K | 9.59K | 86.23K |
| Gross Profit | 103.83K | 237.4K | 562.59K | 538.82K | 275.5K |
| Gross Margin | 68.2% | 56.8% | 99.0% | 98.3% | 76.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 153.62K | 359.05K | 398.28K | 1.1M | 1.32M |
| Depreciation & Amortization | 1.55K | 2.44K | 2.3K | 3.83K | 12.7K |
| EBITDA | (40.89K) | (93.91K) | 174.39K | (558.63K) | (1.08M) |
| EBITDA Margin | -26.8% | -22.5% | 30.7% | -101.9% | -298.5% |
| Operating Income | (49.79K) | (121.65K) | 164.31K | (566.17K) | (1.04M) |
| Operating Margin | -32.7% | -29.1% | 28.9% | -103.2% | -288.5% |
| Interest Income | 258 | 128 | 0 | 20.06K | 9.75K |
| Interest Expense | 40.76K | 29.42K | 0 | 0 | 642 |
| Other Income / Expenses | (33.41K) | (4.11K) | 7.78K | 3.71K | (49.66K) |
| Income Before Tax | (83.2K) | (125.76K) | 172.09K | (562.46K) | (1.09M) |
| Pre-Tax Margin | -54.6% | -30.1% | 30.3% | -102.6% | -302.2% |
| Income Tax Expense | 0 | 0 | 0 | 19.81K | 2.44K |
| Net Income | (83.2K) | (125.76K) | 172.09K | (582.27K) | (1.1M) |
| Net Margin | -54.6% | -30.1% | 30.3% | -106.2% | -302.9% |
| EPS (Basic) | (0.00) | (0.00) | 0.01 | (0.02) | (0.07) |
| EPS (Diluted) | (0.00) | (0.00) | 0.01 | (0.02) | (0.07) |
| Weighted Avg Shares | 27.59M | 27.59M | 27.59M | 27.59M | 16.13M |
| Weighted Avg Shares (Diluted) | 27.59M | 27.59M | 27.59M | 27.59M | 16.13M |
Solowin Holdings Ordinary Share
NASDAQ:AXG
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.